Impact of GLP-1 Agonist on Fat Tissue in Bariatric Surgery Patients
Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery
This study is testing if a GLP-1 medication can change fat tissue and help people who are having bariatric surgery manage their weight and metabolic health better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice, Alpes-maritimes) |
| Trial ID | NCT06278285 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of GLP-1 agonists on adipose tissue in patients undergoing bariatric surgery. It aims to determine whether treatment with a GLP-1 analogue leads to significant changes in oxytocin levels compared to those not receiving the treatment. The research focuses on understanding how these treatments can help normalize weight gain and prevent metabolic syndrome symptoms. Participants will be monitored for their response to the GLP-1 treatment over a specified period.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a BMI greater than 35 and at least one comorbidity, or a BMI greater than 40, who are scheduled for bariatric surgery.
Not a fit: Patients who are pregnant, breastfeeding, or under guardianship will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into effective treatments for obesity and metabolic syndrome.
How similar studies have performed: While the specific approach of this study may be novel, similar studies investigating GLP-1 agonists have shown promising results in obesity management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age. * Patient able to read and understand the information/consent leaflet. * Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40 * Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM. * Membership of a social security scheme * Patient's signed informed consent * For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months. * For non-GLP-1 analogue group: never taken GLP-1 analogues. Exclusion Criteria: * Pregnant or breast-feeding women. * Vulnerable patients (under guardianship) * Patients deprived of liberty
Where this trial is running
Nice, Alpes-maritimes
- CHU de Nice - Hôpital de l'Archet — Nice, Alpes-maritimes, France (Recruiting)
Study contacts
- Principal investigator: Iannelli Antonio, PhD — Clinique Parc Impérial, Service de Chirurgie Digestive
- Study coordinator: ROUX Christian, PhD
- Email: roux.c@chu-nice.fr
- Phone: +3349209220
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.